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TO THE EDITOR- We agree with Boyd and Lacombe that there is a paucity of prospective 
longitudinal data on change in liver fibrosis measured by transient elastography (TE) in 
HIV/hepatitis B (HBV) co-infected patients starting tenofovir, particularly among patients in 
sub-Saharan Africa.
1
 
 
TE has been validated as a non-invasive measure of fibrosis with good diagnostic accuracy in 
HBV using histological hepatic fibrosis scores as the gold standard.
2
 Most data arises from 
Western or Asian settings among mono-infected patients and there is a need for validation 
studies in African populations including in HIV/HBV co-infection to support future 
research.
3,4
 
 
There is mounting evidence of the independent prognostic value of TE in predicting 
subsequent liver related mortality, decompensation and development of hepatocellular 
carcinoma.
5-7
 It may be argued that TE has challenged liver biopsy for position as the gold 
standard in assessing hepatic fibrosis and prognosis, given that a greater area of liver is 
examined by TE and that problems of inter- and intra-observer variability and sampling error 
due to inhomogenous fibrosis that are associated with liver biopsy are less likely to affect 
TE.
8
 Furthermore, TE permits frequent reassessment and can measure of response to therapy, 
so long as the limitations of the technology are considered, including variation with meals 
and false elevation with cholestasis, steatosis and acute transaminitis.
8-11
  
 
The data presented by Boyd et al are interesting and demonstrate highly variable responses 
among French HIV/HBV patients treated with tenofovir, with most of the improvement in TE 
scores occurring within the first year of treatment.
1
 In the data they provide, a number of 
subjects who have increasing TE measurements on treatment and it would be interesting to 
understand the mechanisms, for example, poor adherence or hepatitis C or delta 
superinfection. It would be important to correlate their finding with results of HBV DNA 
suppression; while over 80% of the total cohort under follow up at 6 years (n=172) achieved 
HBV suppression in their accompanying paper, results for this TE subgroup (n=28) are not 
presented.
12
 Their data suggest that there may be limited improvement beyond the first year 
of treatment. This is in contrast to evidence from larger studies of mono-infected subjects that 
showed marked ongoing improvements after the first year and up to five years of treatment.
13
 
If such a finding can be confirmed in a larger sample despite long term HBV suppression, the 
unique immunopathogensis associated with HIV co-infection may be found responsible. 
 
Even if no further improvement is shown to continue beyond the first year, by limiting HBV 
replication among patients with a high rate of lamivudine resistance and virological 
breakthrough, progression of fibrosis and liver related morbidity can be prevented. Our 
finding of high rates of HBV suppression and early regression of fibrosis with tenofovir in 
patients extensively exposed to lamivudine remains highly encouraging.
14
 We agree that long 
term data on HIV/HBV patients treated with tenofovir in sub-Saharan Africa are required and 
we have planned further follow up of the participants of HEPIK including further assessment 
with TE. 
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